Article

Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease

Massachusetts General Hospital, Department of Neurology/Alzheimer's Disease Research Laboratory, Charlestown, Massachusetts 02129, USA.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.75). 02/2012; 32(9):3176-92. DOI: 10.1523/JNEUROSCI.6439-11.2012
Source: PubMed

ABSTRACT Amyloid β (Aβ) peptides, the main pathological species associated with Alzheimer's disease (AD), disturb intracellular calcium homeostasis, which in turn activates the calcium-dependent phosphatase calcineurin (CaN). CaN activation induced by Aβ leads to pathological morphological changes in neurons, and overexpression of constitutively active calcineurin is sufficient to generate a similar phenotype, even without Aβ. Here, we tested the hypothesis that calcineurin mediates neurodegenerative effects via activation of the nuclear transcription factor of activated T-cells (NFAT). We found that both spine loss and dendritic branching simplification induced by Aβ exposure were mimicked by constitutively active NFAT, and abolished when NFAT activation was blocked using the genetically encoded inhibitor VIVIT. When VIVIT was specifically addressed to the nucleus, identical beneficial effects were observed, thus enforcing the role of NFAT transcriptional activity in Aβ-related neurotoxicity. In vivo, when VIVIT or its nuclear counterpart were overexpressed in a transgenic model of Alzheimer's disease via a gene therapy approach, the spine loss and neuritic abnormalities observed in the vicinity of amyloid plaques were blocked. Overall, these results suggest that NFAT/calcineurin transcriptional cascades contribute to Aβ synaptotoxicity, and may provide a new specific set of pathways for neuroprotective strategies.

0 Followers
 · 
184 Views
  • Source
    • "See review Torres-Aleman, 2008; Perl, 2010 ↑Tau-P and NFT's Tran et al., 2011; Johnson et al., 2012b See review Torres-Aleman, 2008; Perl, 2010 Neuronal cell loss Baldwin et al., 1997; Wakade et al., 2010 See review Torres-Aleman, 2008; Perl, 2010 Synapse loss Wakade et al., 2010; Gao et al., 2011 Reddy and Beal, 2008; see review Arendt, 2009 Dendritic spine loss and remodeling Gao et al., 2011; Campbell et al., 2012a Knobloch and Mansuy, 2008; Hudry et al., 2012 Frontiers in "
    [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic brain injury (TBI) results in significant disability due to cognitive deficits particularly in attention, learning and memory, and higher-order executive functions. The role of TBI in chronic neurodegeneration and the development of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS) and most recently chronic traumatic encephalopathy (CTE) is of particular importance. However, despite significant effort very few therapeutic options exist to prevent or reverse cognitive impairment following TBI. In this review, we present experimental evidence of the known secondary injury mechanisms which contribute to neuronal cell loss, axonal injury, and synaptic dysfunction and hence cognitive impairment both acutely and chronically following TBI. In particular we focus on the mechanisms linking TBI to the development of two forms of dementia: AD and CTE. We provide evidence of potential molecular mechanisms involved in modulating Aβ and Tau following TBI and provide evidence of the role of these mechanisms in AD pathology. Additionally we propose a mechanism by which Aβ generated as a direct result of TBI is capable of exacerbating secondary injury mechanisms thereby establishing a neurotoxic cascade that leads to chronic neurodegeneration.
    Frontiers in Aging Neuroscience 07/2013; 5:29. DOI:10.3389/fnagi.2013.00029 · 2.84 Impact Factor
  • Source
    • "Our results, combined with recent work from another group (Hudry et al., 2012), suggest that the targeted delivery of CN or NFAT inhibitors to select brain regions and/or cell types with AAV can help reduce AD-related biomarkers, while also minimizing the possibility of detrimental off-target treatment effects. Because of its specificity, lack of toxicity, and capacity for widespread and long-lasting transgene expression, AAV appears to be an ideal vehicle for directing therapeutics to astrocytes and other cell types. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Astrocytes are the most abundant cell type in the brain and play a critical role in maintaining healthy nervous tissue. In Alzheimer's disease (AD) and most other neurodegenerative disorders, many astrocytes convert to a chronically "activated" phenotype characterized by morphologic and biochemical changes that appear to compromise protective properties and/or promote harmful neuroinflammatory processes. Activated astrocytes emerge early in the course of AD and become increasingly prominent as clinical and pathological symptoms progress, but few studies have tested the potential of astrocyte-targeted therapeutics in an intact animal model of AD. Here, we used adeno-associated virus (AAV) vectors containing the astrocyte-specific Gfa2 promoter to target hippocampal astrocytes in APP/PS1 mice. AAV-Gfa2 vectors drove the expression of VIVIT, a peptide that interferes with the immune/inflammatory calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway, shown by our laboratory and others to orchestrate biochemical cascades leading to astrocyte activation. After several months of treatment with Gfa2-VIVIT, APP/PS1 mice exhibited improved cognitive and synaptic function, reduced glial activation, and lower amyloid levels. The results confirm a deleterious role for activated astrocytes in AD and lay the groundwork for exploration of other novel astrocyte-based therapies.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 11/2012; 32(46):16129-16140. DOI:10.1523/JNEUROSCI.2323-12.2012 · 6.75 Impact Factor
  • The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 07/2012; 32(28):9454-6. DOI:10.1523/JNEUROSCI.2143-12.2012 · 6.75 Impact Factor
Show more